<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>757</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11903615</PubmedId>
            <Abstract>Protective immunity against Mycobacterium tuberculosis infection requires the activation of mycobacterium-specific CD8+ T cells, as well as CD4+ T cells. Therefore, optimizing strategies that stimulate CD8+ T cells recognizing dominant mycobacterial antigens, including secreted proteins, may lead to the development of more effective vaccines against tuberculosis. To generate a viral vaccine that is safe in humans, the early secreted protein, MPT64, was expressed in the attenuated vaccinia virus (VV) strain, modified vaccinia virus Ankara (MVA-64). The immunogenicity of MVA-64 was compared with that of the Western Reserve strain of VV (VVWR-64). The replication-defective MVA-64 was as efficient as VVWR-64 in inducing specific antibodies and cytolytic T-cell responses to a defined H-2-Db-restricted epitope on MTP-64. In addition, priming with MPT64-expressing plasmid DNA (DNA-64), and boosting with either MVA-64 or VVWR-64, markedly enhanced MPT64-specific cytolytic and IFN-gamma-producing CD8+ T-cell responses. These findings suggest that MVA may be a suitable vaccine carrier for stimulating mycobacterium-specific CD8+ T-cell responses and may be particularly relevant for developing vaccines for use in regions endemic for tuberculosis and HIV infection.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>569-75</ArticlePages>
            <ArticleTitle>Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Feng</LastName>
                    <ForeName>C G</ForeName>
                </Author>
                <Author>
                    <LastName>Blanchard</LastName>
                    <ForeName>T J</ForeName>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>G L</ForeName>
                </Author>
                <Author>
                    <LastName>Hill</LastName>
                    <ForeName>A V</ForeName>
                </Author>
                <Author>
                    <LastName>Britton</LastName>
                    <ForeName>W J</ForeName>
                </Author>
            </Authors>
            <Affiliations>Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, Australia.</Affiliations>
            <ArticleChemicalList>Antigens, Bacterial;BCG Vaccine;Vaccines, Attenuated;Viral Vaccines</ArticleChemicalList>
            <ArticleMeshHeadingsList>AIDS-Related Opportunistic Infections(immunology; prevention &amp; control); Animals; Antigens, Bacterial(genetics; immunology); BCG Vaccine(genetics; immunology); CD8-Positive T-Lymphocytes(immunology); Female; Humans; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis(immunology); Tuberculosis(immunology; prevention &amp; control); Vaccines, Attenuated(genetics; immunology); Vaccinia virus(immunology); Viral Vaccines(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>6</Issue>
                <Title>Immunology and cell biology</Title>
                <Issn>1440-1711</Issn>
                <MedlineTa>Immunol Cell Biol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>MPT64&lt;sub&gt;190-198&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FAVTNDGVI</LinearSequence>
                        <StartingPosition>190</StartingPosition>
                        <EndingPosition>198</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAC44034.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>33892</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 570</LocationOfData>
                <EpitopeId>15302</EpitopeId>
                <ReferenceStartingPosition>190</ReferenceStartingPosition>
                <ReferenceEndingPosition>198</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3 and 4</LocationOfData>
                        <TCellId>7836</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAC44034.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>33892</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>467144</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1 or 2 doses of  10&lt;sup&gt;7&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FAVTNDGVI</LinearSequence>
                                            <StartingPosition>190</StartingPosition>
                                            <EndingPosition>198</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAC44034.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33892</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice received recombinant vaccinia virus. In some experiments, a 2nd dose was given 6 weeks later. Splenocytes were harvested 6 weeks later and stimulated in vitro with peptide for 6 days.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>EL-4 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MPT64&lt;sub&gt;190-198&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAVTNDGVI</LinearSequence>
                                        <StartingPosition>190</StartingPosition>
                                        <EndingPosition>198</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC44034.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33892</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results are seen after 1 or 2 doses. Similar results were obtained when the immunization was performed with recombinant Western Reserve (WR) vaccinia expressing MPT64.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>7837</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAC44034.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>33892</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 50 μg of recombinant plasmid and 1 dose of 10&lt;sup&gt;7&lt;/sup&gt; PFU recombinant vaccinia MVA, 6 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FAVTNDGVI</LinearSequence>
                                            <StartingPosition>190</StartingPosition>
                                            <EndingPosition>198</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAC44034.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33892</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Splenocytes were obtained 6 weeks after the last immunization and restimulated with peptide for 6 days.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>EL-4 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MPT64&lt;sub&gt;190-198&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAVTNDGVI</LinearSequence>
                                        <StartingPosition>190</StartingPosition>
                                        <EndingPosition>198</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC44034.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33892</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The responses observed with the heterologous prime-boost regimen were higher than those with two plasmid doses or with two doses of recombinant vaccinia. Similar results were obtained when the boost was performed with recombinant Western Reserve (WR) vaccinia expressing MPT64.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>1548557</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAC44034.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>33892</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 50 μg of recombinant plasmid and 1 dose of 10&lt;sup&gt;7&lt;/sup&gt; PFU recombinant vaccinia WR, 6 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Also 2 doses of recombinant vaccinia (MVA or WR) was tested.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MPT64&lt;sub&gt;190-198&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAVTNDGVI</LinearSequence>
                                        <StartingPosition>190</StartingPosition>
                                        <EndingPosition>198</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC44034.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33892</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar but lower results were obtained when the boost was performed with recombinant MVA than when it was done with recombinant Vaccinia WR. The heterologous prime-boost regime was more efficient than 2 doses of recombinant vaccinia.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

